<DOC>
	<DOCNO>NCT01397539</DOCNO>
	<brief_summary>The primary objective study evaluate safety tolerability range BIIB037 dose administer single intravenous ( IV ) infusion participant mild moderate Alzheimer 's Disease ( AD ) . Secondary objective study study population ass pharmacokinetics ( PK ) evaluate immunogenicity BIIB037 single-dose administration .</brief_summary>
	<brief_title>Single Ascending Dose Study BIIB037 Participants With Alzheimer 's Disease</brief_title>
	<detailed_description>BIIB037 investigational product develop treatment Alzheimer 's disease ( AD ) . BIIB037 fully human immunoglobulin gamma 1 ( IgG1 ) monoclonal antibody selective fibrillar form beta amyloid ( AÃŸ ) .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Key Must ambulatory Must clinical diagnosis Alzheimer 's Disease ( AD ) consistent follow : 1 . Probable Alzheimer 's Disease ( AD ) , accord National Institute Neurological Communicative Disease Stroke Alzheimer 's Disease Related Disorders Association ( NINCDSADRDA ) criteria [ McKhann et al . 1984 ] . 2 . Dementia Alzheimer 's type , accord Diagnostic Statistical Manual Mental DisordersText Revision ( DSM IV TR ) criteria [ American Psychiatric Association 2000 ] Subject ( subject 's permanent caregiver ) ability understand purpose risk study provide sign date informed consent ( assent ) authorization use protect health information ( PHI ) accordance national local subject privacy regulation . Must Mini Mental State Examination ( MMSE ) score 14 26 inclusive . Key Any medical neurological condition Alzheimer 's Disease ( AD ) opinion Investigator could contribute cause subject 's dementia ( e.g. , medication use , vitamin B12 deficiency , abnormal thyroid function , stroke cerebrovascular condition , diffuse Lewy body disease , head trauma ) . History within past 6 month evidence clinically significant psychiatric illness ( e.g. , major depression , schizophrenia , bipolar affective disorder ) . Subject currently live nursing home . Blood donation ( 1 unit ) within 1 month prior Screening Participation drug , biologic , device , clinical study treatment investigational drug approve therapy investigational use within 30 day ( 5 half life , whichever long ) prior Screening , and/or participation clinical study involve experimental medication AD within 60 day ( 5 half life , whichever long ) prior Screening . Any contraindication brain Magnetic Resonance Imaging ( MRI ) e.g. , pacemaker ; NonMagnetic Resonance Imaging ( MRI ) compatible aneurysm clip , artificial heart valve , metal foreign body ; claustrophobia ) . NOTE : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>